Ultragenyx Pharmaceutical Statistics
Total Valuation
RARE has a market cap or net worth of $3.94 billion. The enterprise value is $4.10 billion.
Important Dates
The last earnings date was Thursday, February 13, 2025, after market close.
| Earnings Date | Feb 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RARE has 92.50 million shares outstanding. The number of shares has increased by 23.11% in one year.
| Current Share Class | 92.50M |
| Shares Outstanding | 92.50M |
| Shares Change (YoY) | +23.11% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 3.39% |
| Owned by Institutions (%) | 95.45% |
| Float | 89.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.88 |
| Forward PS | 5.84 |
| PB Ratio | 15.43 |
| P/TBV Ratio | 120.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.37, with a Debt / Equity ratio of 3.47.
| Current Ratio | 2.37 |
| Quick Ratio | 2.13 |
| Debt / Equity | 3.47 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.50 |
Financial Efficiency
Return on equity (ROE) is -211.71% and return on invested capital (ROIC) is -28.12%.
| Return on Equity (ROE) | -211.71% |
| Return on Assets (ROA) | -22.37% |
| Return on Invested Capital (ROIC) | -28.12% |
| Return on Capital Employed (ROCE) | -46.23% |
| Revenue Per Employee | $439,052 |
| Profits Per Employee | -$446,068 |
| Employee Count | 1,276 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 19.62 |
Taxes
In the past 12 months, RARE has paid $1.60 million in taxes.
| Income Tax | 1.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -11.03% in the last 52 weeks. The beta is 0.59, so RARE's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -11.03% |
| 50-Day Moving Average | 43.71 |
| 200-Day Moving Average | 47.25 |
| Relative Strength Index (RSI) | 44.77 |
| Average Volume (20 Days) | 656,550 |
Short Selling Information
The latest short interest is 4.16 million, so 4.50% of the outstanding shares have been sold short.
| Short Interest | 4.16M |
| Short Previous Month | 4.25M |
| Short % of Shares Out | 4.50% |
| Short % of Float | 4.66% |
| Short Ratio (days to cover) | 4.18 |
Income Statement
In the last 12 months, RARE had revenue of $560.23 million and -$569.18 million in losses. Loss per share was -$6.29.
| Revenue | 560.23M |
| Gross Profit | -214.36M |
| Operating Income | -535.97M |
| Pretax Income | -586.86M |
| Net Income | -569.18M |
| EBITDA | -500.43M |
| EBIT | -535.97M |
| Loss Per Share | -$6.29 |
Full Income StatementBalance Sheet
The company has $610.03 million in cash and $910.01 million in debt, giving a net cash position of -$164.98 million or -$1.78 per share.
| Cash & Cash Equivalents | 610.03M |
| Total Debt | 910.01M |
| Net Cash | -164.98M |
| Net Cash Per Share | -$1.78 |
| Equity (Book Value) | 262.30M |
| Book Value Per Share | 2.76 |
| Working Capital | 472.97M |
Full Balance SheetCash Flow
| Operating Cash Flow | -414.19M |
| Capital Expenditures | -7.49M |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
Gross margin is -38.26%, with operating and profit margins of -95.67% and -101.60%.
| Gross Margin | -38.26% |
| Operating Margin | -95.67% |
| Pretax Margin | -101.31% |
| Profit Margin | -101.60% |
| EBITDA Margin | -89.33% |
| EBIT Margin | -95.67% |
| FCF Margin | n/a |
Dividends & Yields
RARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.11% |
| Shareholder Yield | -23.11% |
| Earnings Yield | -14.45% |
| FCF Yield | n/a |
Dividend DetailsAnalyst Forecast
The average price target for RARE is $93.13, which is 118.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $93.13 |
| Price Target Difference | 118.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 39.00% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RARE has an Altman Z-Score of -2.09 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.09 |
| Piotroski F-Score | 3 |